Microcap Ledger Vyome Holdings, Inc $HIND
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Clemente, CA
- Fiscal year end
- December 31
- Shares outstanding
- 7,018,528 [10-Q 2026-08-12]
What the company doesAI summary of filing
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company developing treatments for immune-inflammatory and rare diseases. The company's lead program, VT-1953, is a topical gel in late-stage development for malignant fungating wounds in advanced cancer patients, with positive Phase 2 results and plans for FDA discussions on a Phase 3 trial design in the first half of 2026. The company also has a pre-IND ophthalmic drops program (VT-1908) for anterior uveitis and a Phase 3-ready acne program (VB-1953). Additionally, Vyome has commercialized two reformulated topical antifungal products in India through a licensing agreement with Sun Pharma, generating revenue from net service fees on product sales rather than from product development, as the company has no FDA-approved products. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $58.5K | −$1.65M | −$2.34M | $7.89M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $319.7K | −$10.26M | −$3.75M | $4.98M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $256.9K | −$1.45M | −$614.1K | $101.9K | [10-K 2026-03-18] |
- Quarterly cash burn
- −$1.17M
- Cash runway Estimate
- ~20.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 712,680 | [10-Q 2024-11-14] |
| 2025-04-02 | 11,276,248 | [10-K 2025-04-04] |
| 2025-05-14 | 738,277 | [10-Q 2025-05-20] |
| 2025-08-08 | 2,693,338 | [10-Q 2025-08-14] |
| 2025-11-13 | 5,644,494 | [10-Q 2025-11-14] |
| 2026-03-17 | 7,018,528 | [10-K 2026-03-18] |
| 2026-05-12 | 7,018,528 | [10-Q 2026-05-12] |
| 2026-08-12 | 7,018,528 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-11-06; no effectiveness notice found in EDGAR [S-3 2025-11-06]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-30] |
| 2024-12-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-02] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-08-15 | Jolly Mohanjit | grant | 454,456 | — | [4 2025-11-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-28 | 8-K | Director or officer change |
| 2026-08-25 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-05-29 | 8-K | Results of operations |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-04-29 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-03-31 | DEF 14A | Proxy statement |
| 2026-03-20 | PRE 14A | Proxy statement |
| 2026-03-18 | 10-K | Annual report |
| 2026-02-25 | 8-K | Material agreement entered; Other events |
| 2026-02-13 | 8-K | Regulation FD disclosure |
| 2026-01-28 | 8-K | Regulation FD disclosure; Other events |
Alerts for $HIND
Email me when Vyome Holdings, Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.